2.6.1.19	(1R,4S)-4-amino-2-cyclopentene-1-carboxylic acid + 2-oxoglutarate	analogue of 4-aminobutanoate, vigabatrin	Sus scrofa	? + L-glutamate	-	?	354090	
2.6.1.19	(4R)-4-amino-1-cyclopentene-1-carboxylic acid + 2-oxoglutarate	analogue of 4-aminobutanoate, vigabatrin	Sus scrofa	4-oxo-1-cyclopentene1-carboxylic acid + L-glutamate	-	?	354091	
2.6.1.19	(R)-4-amino-3-fluorobutanoic acid	-	Sus scrofa	4-aminobut-2-enoic acid + HF	-	?	411117	
2.6.1.19	(R,S)-4-amino-3-fluorobutanoic acid	neither enantiomer is a substrate for transamination. The rate of elimination of HF from the (R)-enantiomer is at least 10 times greater than that for the (S)-enantiomer	Sus scrofa	4-aminobut-2-enoic acid + HF	-	?	395150	
2.6.1.19	(S)-4-amino-4,5-dihydro-2-thiophenecarboxylic acid + 2-oxoglutarate	mechanism-based inactivator that partly undergoes inactivation	Sus scrofa	4-oxo-4,5-dihydro-2-thiophenecarboxylic acid + L-glutamate	-	?	354089	
2.6.1.19	1H-tetrazole-5-butanamine + 2-oxoglutarate	-	Sus scrofa	(1H-tetrazol-5-yl)-butyraldehyde + L-glutamate	-	?	378865	
2.6.1.19	1H-tetrazole-5-ethanamine + 2-oxoglutarate	-	Sus scrofa	(1H-tetrazol-5-yl)-acetaldehyd + L-glutamate	-	?	378866	
2.6.1.19	1H-tetrazole-5-propanamine + 2-oxoglutarate	-	Sus scrofa	(1H-tetrazol-5-yl)-propionaldehyde + L-glutamate	-	?	378867	
2.6.1.19	3-(aminomethyl)benzoic acid + 2-oxoglutarate	3.4% of the activity with 4-aminobutanoate	Sus scrofa	3-(iminomethyl)benzoic acid + L-glutamate	-	?	395698	
2.6.1.19	3-aminoisobutanoate + 2-oxoglutarate	-	Mus musculus	L-glutamate + 3-oxoisobutanoate	-	r	354087